Abstract
The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 441-450 |
| Number of pages | 10 |
| Journal | Experimental Gerontology |
| Volume | 42 |
| Issue number | 5 SPEC. ISS. |
| DOIs | |
| State | Published - May 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Aging
- Breast cancer
- Cancer vaccines
- Immune system
- Preclinical models
ASJC Scopus subject areas
- Aging
- Medicine(all)
Cite this
Cancer vaccines in old age. / Gravekamp, Claudia.
In: Experimental Gerontology, Vol. 42, No. 5 SPEC. ISS., 05.2007, p. 441-450.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cancer vaccines in old age
AU - Gravekamp, Claudia
PY - 2007/5
Y1 - 2007/5
N2 - The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.
AB - The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.
KW - Aging
KW - Breast cancer
KW - Cancer vaccines
KW - Immune system
KW - Preclinical models
UR - http://www.scopus.com/inward/record.url?scp=34147164486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34147164486&partnerID=8YFLogxK
U2 - 10.1016/j.exger.2006.11.009
DO - 10.1016/j.exger.2006.11.009
M3 - Article
VL - 42
SP - 441
EP - 450
JO - Experimental Gerontology
JF - Experimental Gerontology
SN - 0531-5565
IS - 5 SPEC. ISS.
ER -